Genmab A/S
CSE:GMAB

Watchlist Manager
Genmab A/S Logo
Genmab A/S
CSE:GMAB
Watchlist
Price: 1 483.5 DKK 2.49% Market Closed
Market Cap: 97.7B DKK
Have any thoughts about
Genmab A/S?
Write Note

Genmab A/S
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Genmab A/S
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Genmab A/S
CSE:GMAB
Total Equity
kr31B
CAGR 3-Years
15%
CAGR 5-Years
30%
CAGR 10-Years
33%
Zealand Pharma A/S
CSE:ZEAL
Total Equity
kr8.9B
CAGR 3-Years
96%
CAGR 5-Years
45%
CAGR 10-Years
40%
Ascendis Pharma A/S
NASDAQ:ASND
Total Equity
-€321.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Total Equity
kr10.4B
CAGR 3-Years
22%
CAGR 5-Years
39%
CAGR 10-Years
27%
F
Fluoguide AS
STO:FLUO
Total Equity
kr12.7m
CAGR 3-Years
42%
CAGR 5-Years
351%
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Total Equity
kr104.8m
CAGR 3-Years
11%
CAGR 5-Years
11%
CAGR 10-Years
12%
No Stocks Found

Genmab A/S
Glance View

Market Cap
94.2B DKK
Industry
Biotechnology

Genmab A/S is a cutting-edge biotechnology company based in Denmark, renowned for its pioneering approach to developing differentiated antibody therapies for the treatment of cancer. Founded in 1999, the company focuses on harnessing the power of the immune system to combat various malignancies. Its flagship product, Darzalex (daratumumab), has transformed treatment protocols for multiple myeloma, achieving robust sales and establishing Genmab as a formidable player in the oncology landscape. The company's innovative platform combines proprietary technologies and skilled teams to create next-generation therapies, underscoring its commitment to improving patients' lives through targeted and effective cancer treatment solutions. As Genmab continues to build on its success, it is also expanding its pipeline with a diverse array of promising assets in various stages of clinical development. Not only does this validate its research capabilities, but it also positions Genmab for substantial future growth. The company's strategic collaborations with major pharmaceutical partners, such as Johnson & Johnson, further amplify its reach and resource capabilities, fostering a collaborative approach to accelerate drug development. With a solid financial standing and a focus on sustained innovation, Genmab A/S presents an intriguing investment opportunity for those looking to tap into the evolving landscape of biotechnology and oncology therapeutics.

GMAB Intrinsic Value
2 507.16 DKK
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Genmab A/S's Total Equity?
Total Equity
31B DKK

Based on the financial report for Jun 30, 2024, Genmab A/S's Total Equity amounts to 31B DKK.

What is Genmab A/S's Total Equity growth rate?
Total Equity CAGR 10Y
33%

Over the last year, the Total Equity growth was 8%. The average annual Total Equity growth rates for Genmab A/S have been 15% over the past three years , 30% over the past five years , and 33% over the past ten years .

Back to Top